The FDA’s weak drug manufacturing oversight is a potentially deadly problem
- Written by Adrian V. Hernandez, Associate Professor of Comparative Effectiveness and Outcomes Research, University of Connecticut
Though drug recalls are relatively uncommon in the U.S., reduced inspections increase the likelihood of manufacturing errors that slip through the cracks.AP Photo/Rafiq MaqboolThe latest setback for Johnson & Johnson’s COVID-19 vaccine was the U.S. Food and Drug Administration’s order on June 11, 2021, to discard 60 million doses th...
Read more: The FDA’s weak drug manufacturing oversight is a potentially deadly problem
